In Q1 FY2026 (ended March 31, 2026), Nektar Therapeutics reported revenue of $10.9 million, up 3.8% year-over-year. Net loss was $44.9 million, improving 11.7% from the prior year. Operating loss was $39.1 million, and diluted EPS was -$1.82. Cash and equivalents totaled $149.6 million, with equity of $576.2 million.
•Revenue increased 3.8% YoY to $10.9 million.
•Net loss improved 11.7% to $44.9 million.
•Diluted EPS was -$1.82.
•Cash and equivalents stood at $149.6 million.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Nektar Therapeutics, a biopharmaceutical company focuses on discovering and developing medicines in the field of immunotherapy in the United States and globally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases. Its portfolio also includes NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis, NKTR-0166 to treat autoimmune disease, NKTR-422 to treat fibrotic diseases, and NKTR-255 to treat solid tumors and large b-cell lymphoma.
It has collaboration agreements with Takeda Pharmaceutical Company Ltd. Its portfolio also includes AstraZeneca AB, UCB Pharma, F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, and Merck KGaA. Incorporated in 1990, the company is headquartered in San Francisco, California.
Nektar Therapeutics is a biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. Its lead product candidate is rezpegaldesleukin, currently in Phase 2b trials for treating underlying immune system imbalances in people with autoimmune disorders and inflammatory diseases. The company also has a pipeline including NKTR-0165 for ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 for autoimmune diseases; NKTR-422 for fibrotic diseases; and NKTR-255 for solid tumors and large B-cell lymphoma. Nektar collaborates with major pharmaceutical companies such as Takeda, AstraZeneca, Roche, Pfizer, Bristol-Myers Squibb, and Merck KGaA to advance its drug candidates.
Where is Nektar Therapeutics (NKTR) listed and what currency is used?
Nektar Therapeutics is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol NKTR. The trading currency is the US Dollar (USD), as the company is headquartered in the United States and its shares are traded on a US exchange. Investors can buy and sell NKTR shares during regular market hours on Nasdaq, and the stock price is quoted in USD.
What sector and industry does Nektar Therapeutics (NKTR) belong to?
Nektar Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, Nektar focuses on using biological processes and living organisms to develop therapies, particularly in immunotherapy. Its work involves researching and developing drugs that modulate the immune system to treat autoimmune diseases, inflammatory conditions, and cancers. This places it among other biotech firms that aim to create innovative treatments for unmet medical needs.
Where is Nektar Therapeutics (NKTR) headquartered and what markets does it serve?
Nektar Therapeutics is headquartered in San Francisco, California, United States. The company was incorporated in 1990 and serves markets both in the United States and globally. Its research and development efforts target patients worldwide, with clinical trials and collaborations extending internationally. The company's global reach is supported by partnerships with pharmaceutical companies such as Takeda (Japan), AstraZeneca (UK/Sweden), Roche (Switzerland), and Merck KGaA (Germany), indicating its presence in multiple regions.
How does Nektar Therapeutics (NKTR) generate revenue or advance its pipeline?
Nektar Therapeutics generates revenue primarily through collaboration agreements with major pharmaceutical companies. The company has partnerships with Takeda, AstraZeneca, UCB Pharma, Roche, Bausch Health, Pfizer, Bristol-Myers Squibb, and Merck KGaA. These collaborations typically involve upfront payments, milestone payments, and royalties on future product sales. Nektar's business model focuses on discovering and developing immunotherapy drugs, then leveraging partners' resources for late-stage development and commercialization. Its pipeline includes candidates for autoimmune diseases, inflammatory conditions, fibrotic diseases, and cancers, with rezpegaldesleukin being the most advanced.